savepiginvest

Targovax has the cheapest oncolytic virus on the market

Lång
savepiginvest Uppdaterad   
OSL:CRNA   CIRCIO HOLDING ASA
ONCOS-102 is one of the most promising oncolytic viruses with >200 patients treated.
Targovax stock has been under pressure for years after equity offerings at fairly low pricing, but has been making a strong move recently, quite without many investors taking notice.
Norwegian Biotech especially in the field of cancer immunotherapy may be ready for a new round of interest after the recent news about Vaccibody partnering with Genentech.
Handel aktiv:
Positive news last night from Targovax, webcast in 30 minutes from now

Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients
· Tumor responses observed in 7 out of 20 evaluable patients, resulting in best
objective response rate (ORR) of 35%
· Systemic effects observed in multiple patients, including two examples where
a non-injected lesion completely regressed
· An online presentation by Targovax's management will take place at 10:00 CET
2 December 2020 (details below)
Handel aktiv:
Nice bounce today, stay in the trade
Handel aktiv:
Targovax received FDA Fast track designation for Oncos 102!

Stay in trade.

Frånsägelse av ansvar

Informationen och publikationerna är inte avsedda att vara, och utgör inte heller finansiella, investerings-, handels- eller andra typer av råd eller rekommendationer som tillhandahålls eller stöds av TradingView. Läs mer i Användarvillkoren.